First-pass extracted concept

acute myeloid leukemia immunotherapy

Candidate: concept label1 source documents4 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

AML immunotherapy

Evidence Snippets

The clinical efficacy of immunotherapy in acute myeloid leukemia (AML) remains significantly limited by early relapse and treatment-associated toxicities.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1limitationsupports2025Source 1DOI PubMed

The clinical efficacy of immunotherapy in acute myeloid leukemia is significantly limited by early relapse and treatment-associated toxicities.

Claim 2modality scopesupports2025Source 1DOI PubMed

Therapeutic modalities discussed for AML immunotherapy include immunoconjugates, bispecific T-cell engagers, and CAR-T cells.

Claim 3scopesupports2025Source 1DOI PubMed

Recent AML immunotherapy advances discussed in the source include antibody-based and cell-based approaches focused on established targets CD33, CD123, and CLL1 and emerging targets including CD7, CD70, CD38, and FLT3.

Claim 4strategysupports2025Source 1DOI PubMed

Proposed strategies to enhance AML immunotherapy efficacy include combination therapies, structural optimization of CAR constructs, functional enhancement of CAR-T cells, identification of novel targets, and development of next-generation cellular therapies.